| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.JAUT.2010.06.018 |
| P698 | PubMed publication ID | 20638240 |
| P50 | author | Josef S Smolen | Q66753681 |
| P2093 | author name string | Michael Bonelli | |
| Clemens Scheinecker | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| pathogenesis | Q372016 | ||
| P304 | page(s) | 269-275 | |
| P577 | publication date | 2010-07-16 | |
| P1433 | published in | Journal of Autoimmunity | Q15716783 |
| P1476 | title | Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells | |
| P478 | volume | 35 |
| Q35023185 | A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus |
| Q92126889 | A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus |
| Q26786188 | Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research |
| Q38023853 | Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. |
| Q38690844 | Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. |
| Q43736626 | Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells |
| Q92239639 | CD4+CD25+LAG3+ T Cells With a Feature of Th17 Cells Associated With Systemic Lupus Erythematosus Disease Activity |
| Q47146306 | Case report for recurrent and new-onset SLE patients treated by high-dose glucocorticoid therapy: Characteristics of peripheral TCR beta chain CDR3 repertoires |
| Q34221885 | Compensatory T-cell regulation in unaffected relatives of SLE patients, and opposite IL-2/CD25-mediated effects suggested by coreferentiality modeling |
| Q53156988 | Composition and variation analysis of TCR β-chain CDR3 repertoire in the thymus and spleen of MRL/lpr mouse at different ages. |
| Q38293284 | Current role of rituximab in systemic lupus erythematosus |
| Q52573372 | Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. |
| Q35557975 | Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus |
| Q37609039 | Effects of N-acetyl-seryl-asparyl-lysyl-proline on blood pressure, renal damage, and mortality in systemic lupus erythematosus |
| Q34154776 | Effects of cystamine on antioxidant activities and regulatory T cells in lupus-prone mice |
| Q38192683 | Emerging biological therapies for systemic lupus erythematosus |
| Q34401977 | Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients |
| Q42518281 | Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus |
| Q39018591 | Foxp3, Regulatory T Cell, and Autoimmune Diseases |
| Q52584033 | Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis. |
| Q50919779 | Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice. |
| Q30424263 | HLA-DR3 restricted T cell epitope mimicry in induction of autoimmune response to lupus-associated antigen SmD |
| Q38655827 | MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus |
| Q37626256 | MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro |
| Q99711500 | Myeloid-Derived Suppressor Cells Promote the Progression of Primary Membranous Nephropathy by Enhancing Th17 Response |
| Q37697695 | Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders |
| Q35309470 | Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside |
| Q30425180 | Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. |
| Q39271124 | Quantitative and functional analysis of CD69+ T regulatory lymphocytes in patients with periodontal disease |
| Q34976836 | Reflections on Lupus 2013: butterflies, wolves and prophecies |
| Q48668293 | Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation |
| Q35344378 | Regulatory T cell-deficient scurfy mice develop systemic autoimmune features resembling lupus-like disease |
| Q38265968 | Regulatory T cells in systemic lupus erythematosus |
| Q50129651 | Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis |
| Q90179115 | Risk of major autoimmune diseases in female breast cancer patients: A nationwide, population-based cohort study |
| Q37883681 | Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice |
| Q38021183 | Role of TWEAK in lupus nephritis: a bench-to-bedside review |
| Q58780764 | Serum Midkine Levels in Systemic Lupus Erythematosus |
| Q38051261 | The autoimmune side of heart and lung diseases |
| Q27693310 | The deleterious role of basophils in systemic lupus erythematosus |
| Q87646214 | The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease |
| Q38350483 | The impact of biological therapy on regulatory T cells in rheumatoid arthritis |
| Q37475806 | The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. |
| Q33652093 | The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus |
| Q37967566 | The therapeutic potential of epigenetics in autoimmune diseases. |
| Q38497409 | Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent |
| Q37974990 | Treatment of systemic lupus erythematosus: new advances in targeted therapy |
| Q41247616 | Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives |
| Q38192656 | Update on B-cell targeted therapies for systemic lupus erythematosus |
| Q53148600 | [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance]. |
Search more.